Stephan Urban

About Stephan Urban

Stephan Urban, With an exceptional h-index of 61 and a recent h-index of 49 (since 2020), a distinguished researcher at Ruprecht-Karls-Universität Heidelberg, specializes in the field of Virology, Hepatology, Hepatitis B Virus.

His recent articles reflect a diverse array of research interests and contributions to the field:

CARs derived from broadly neutralizing, human monoclonal antibodies identified by single B cell sorting target hepatitis B virus-positive cells

Lipopeptides for use in treating liver diseases and cardiovascular diseases

Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP

Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies

Structure of hepatitis B/D antiviral drug Bulevirtide bound to its receptor protein NTCP

Molecular determinants within the C-termini of L-HDAg that regulate hepatitis D virus replication and assembly

Effect of variants in LGP2 on MDA5-mediated activation of interferon response and suppression of hepatitis D virus replication

Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections

Stephan Urban Information

University

Position

Full Professor for translational Virology

Citations(all)

14915

Citations(since 2020)

7580

Cited By

10253

hIndex(all)

61

hIndex(since 2020)

49

i10Index(all)

126

i10Index(since 2020)

101

Email

University Profile Page

Google Scholar

Stephan Urban Skills & Research Interests

Virology

Hepatology

Hepatitis B Virus

Top articles of Stephan Urban

CARs derived from broadly neutralizing, human monoclonal antibodies identified by single B cell sorting target hepatitis B virus-positive cells

Frontiers in Immunology

2024/4/22

Lipopeptides for use in treating liver diseases and cardiovascular diseases

2020/12/10

Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP

Nature Communications

2024/3/20

Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies

Journal of Hepatology

2024/2/8

Stephan Urban
Stephan Urban

H-Index: 43

Structure of hepatitis B/D antiviral drug Bulevirtide bound to its receptor protein NTCP

bioRxiv

2024

Molecular determinants within the C-termini of L-HDAg that regulate hepatitis D virus replication and assembly

JHEP Reports

2024/1/1

Effect of variants in LGP2 on MDA5-mediated activation of interferon response and suppression of hepatitis D virus replication

Journal of Hepatology

2023/1/1

Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections

Gut

2023/6/1

Stephan Urban
Stephan Urban

H-Index: 43

Magnus Johansson
Magnus Johansson

H-Index: 12

Quantification of the hepatitis B virus cccDNA: evidence-based guidelines for monitoring the key obstacle of HBV cure

Gut

2023/5/1

Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a …

The Lancet Infectious Diseases

2023/1/1

An RNA-based system to study hepatitis B virus replication and evaluate antivirals

Science Advances

2023/4/12

Stephan Urban
Stephan Urban

H-Index: 43

Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers

Frontiers in Pharmacology

2023/4/6

Matthias Schwab
Matthias Schwab

H-Index: 24

Stephan Urban
Stephan Urban

H-Index: 43

In vitro cell culture models to study hepatitis B and D virus infection

2023/4/5

Hongbo Guo
Hongbo Guo

H-Index: 19

Stephan Urban
Stephan Urban

H-Index: 43

Method and means for the rapid detection of HDV infections

2023/12/12

Hepatitis D infection induces IFN-β-mediated NK cell activation and TRAIL-dependent cytotoxicity

Frontiers in immunology

2023/12/8

Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDV

JHEP Reports

2023/11/1

Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice

Journal of Hepatology

2023/11/1

Hepatitis delta: Epidemiology to recent advances in therapeutic agents

2023/10/1

Stephan Urban
Stephan Urban

H-Index: 43

No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta

Journal of Hepatology

2023/9/1

Conjugate compounds for preventing and/or treating hbv and/or hdv infections, liver diseases andfor targeting ntcp

2023/7/6

See List of Professors in Stephan Urban University(Ruprecht-Karls-Universität Heidelberg)

Co-Authors

academic-engine